Cloud-based secure payments technology developer PCI-Pal (LON: PCIP) did better than expected in 2025-26 and grew revenues 14% to £24.6m, which means the expected loss has been reduced to £800,000. Annualised recurring revenues were 29% higher at £24.4m, providing a strong base for 2026-27 forecast earnings of £27m, which will be reassessed when the full year figures are published. Net cash is £4m. The momentum continues, especially in the US. The share price rebounded 15.9% to 51p.
Oxford BioDynamics (LON: OBD) has signed the first agreement for the use of EpiSwitch Orion, which is a cloud-based 3D genomics platform used for biomarker discovery in psoriatic arthritis. The buyer is a government-funded research programme. The share price gained 12.5% to 0.135p.
Staffing company Empresaria (LON: EMR) is set to beat expectations after a good first half. Management estimates that the 2026 pre-tax profit should be at least £5.2m, which is 27% better than forecast. Net debt is £17m. The share price recovered 11.1% to 25p.
Fluidpower products distributor Flowtech Fluidpower (LON: FLO) grew like for like sales by 13% in the first half as the company gains market share. Overall sales were 24% ahead at £70.4m. This was despite the lack of sales to two bridge infrastructure projects, which are likely to come through in the second half. Full year pre0tax profit is set to jump from £1.7m to £4m. The share price rose 9.32% to 64.5p.
FALLERS
Automotive testing and simulation products supplier AB Dynamics (LON: ABDP) says trading has become more challenging due to reduced customer confidence and logistics problems relating to the Middle East. Timelines for decisions are getting longer and hitting short tern orders. This means that full year revenues will be in the range £90m-£95m compared with consensus of £116.7m, although that figure includes the testing services business in China that AB Dynamics is exiting – revenues of £4m are estimated. Cost reductions should keep the adjusted operating margin at around 20%. The share price dived 23.9% to 811.5p.
ECR Minerals (LON: ECR) is accelerating the development of the Maddens gold project in Queensland through trial alluvial operations at the Brothers mining lease. This will involve the relocation of assets from the Raglan project to focus on the higher grade potential. There could be around 100,000 cubic metres of minable material. The share price declined 9.76% to 0.185p.
Premier African Minerals (LON: PREM) says that it will not commence plant operations at the Zulu lithium and tantalum project in July. Talks continue with Canmax over another extension of the long stop date for the prepayment and offtake arrangements. This will help with attempts to attract strategic investors. The plant will only start operating when the Canmax discussions are concluded. The operational efficiency and reliability of the plant is still being improved. Ore inventories are being built up. The share price fell 7.89% to 0.0175p.
Asthma and COPD testing devices developer Niox Group (LON: NIOX) says interim revenues fell 4% to £24m, due to lower research revenues because of the focus on clinical revenues. EBITDA fell from £9.2m to £8.3m. NIOX PRO regulatory approvals are expected in the US and Japan later in the year and this will unlock further demand. The CE Mark has already be obtained. A return of excess capital is planned in the second half. Net cash was £16.8m at the end of June 2026. The share price slipped 4.95% to 61.4p.